Trial Profile
Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms ATM-Cog
- 24 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jan 2013 New trial record